OptoCeutics is pleased to announce the delivery of 26 devices to Zealand University Hospital for the continuation of our ALZLIGHT pilot clinical trial. Thank you to our amazing team who have worked tirelessly to make this happen!
(ClinicalTrials.gov ID: NCT04574921).
Many thanks to our clinical partners, university partners, investors, and other stakeholders for supporting the project from the very beginning of 2018. The focus of ALZLIGHT will be on the safety of the intervention, the feasibility of the proposed intervention time and method, and indication of effectiveness. We expect to have tested it on 14 people by the end of 2021, which will complete Phase 1 of the clinical trial.
The ALZLIGHT study starts shortly after very promising results from another research group at MIT. Their study, OVERTURE, showed major changes in cognition and functional goals in patients with mild to moderate Alzheimer’s disease by means of gamma frequency neuromodulation. OVERTURE, which includes 76 patients with mild to moderate AD, has shown a significant 84% slowdown in functional decline in ADCS-ADL score over a 6-month treatment period, as well as a significant 83% slowdown in memory and cognitive decline measured by MMSE score compared to a placebo group, as well as a 61% reduction in total brain atrophy and volumetric loss associated with Alzheimer’s progression.
Read more about OVERTURE here.